Genautica Rx Information

Being in the suburb of Los Angeles has many advantages, such as close proximity to Hollywood, Pasadena, Silicon Valley and the Biotech Hub of San Diego. Genautica has seed-funded Diagnomics, a biotech company employing an highly qualified team of scientists including early pioneers in sequencing the human genome. Through its investment in Diagnomics, Genautica has also been an early partner with the EONE-Diagnomics Genome Center (EDGC) in Korea, which went public in 2018 on KOSDAQ, the Korean tech stock market. Scientific advancement in genomic medicine is enabling to diagnose diseases earlier and more precisely. That in turn, allows to predict health risk more accurately, and to ultimately achieve a truly personalized treatment. In fact, several recent technology breakthroughs in next generation sequencing have accelerated the adaptation of personal genomics, and it is expected that the cost to do whole genome sequencing will fall to less than $500 within the next few years. Accurate and affordable sequencing coupled with an advanced genome analysis, will ultimately usher in a new era of personalized medicine. Diagnomics Image 1